Sergio Quezada

Vermögen: 466 571 $ am 31.03.2024

49 Jahre

Consumer Services

Health Technology

Profil

Sergio Quezada is the founder of Achilles Therapeutics UK Ltd.
(founded in 2016) and Achilles Therapeutics Plc (founded in 2020), where he holds the title of Chief Scientific Officer.
He is currently a Professor-Cancer Institute at University College London since 2011.
Dr. Quezada obtained his undergraduate degree from Pontificia Universidad Católica de Chile and his doctorate from Dartmouth Medical School.

Bekannte Unternehmensbeteiligungen

Unternehmen	Datum	Anzahl der Aktien	Bewertung	Datum der Bewertung
ACHILLES THERAPEUTICS PLC 0,92%	01.02.2023	373 257 ( 0,92% )	466 571 $	31.03.2024

Aktive Positionen von Sergio Quezada

Unternehmen	Position	Beginn
ACHILLES THERAPEUTICS PLC	Founder	01.11.2020
University College London	Corporate Officer/Principal	01.01.2011

Alle aktiven Positionen von Sergio Quezada

Ehemalige bekannte Positionen von Sergio Quezada

Unternehmen	Position	Ende
Achilles Therapeutics UK Ltd. Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom.	Founder	-